ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1570

Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study

Thibaud Depinoy1, Valérie Devauchelle-Pensec2, Sandrine Jousse-Joulin3, Thierry Marhadour1, Dewi Guellec3, Pascale Marcorelles1, Jacques-Olivier Pers2, Alain Saraux3 and Divi Cornec4, 1CHU Brest, Brest, France, 2U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, 3Rheumatology, CHU Brest, Brest, France, 4Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Diagnostic Tests and Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To determine whether the repetition of minor salivary gland biopsy (MSGB) has a clinical diagnostic utility in patients with suspicion of primary Sjögren’s syndrome (pSS).

Methods: We studied retrospectively patients with suspected pSS who had routinely benefited from two MSGB at our institution between January 1, 1990 and January 14, 2015. We collected for each of these patients the clinical and biological features and the results of the two MSGB, as well as the diagnoses performed by the evaluating physician after each biopsy. We compared the characteristics of patients with and without a clinical diagnosis of pSS after the first MSGB, and analysed the changes between the two MSGB.

Results: We included 93 patients, 18 pSS and 75 npSS (clinical diagnosis after the first MSGB). pSS patients were significantly older and more often had renal or pulmonary involvement, and, as expected, had more often rheumatoid factor, anti-SSA and anti-SSB antibodies and positive biopsy with focus score ≥ 1 or Chisholm score > 2. The mean time between the 2 MSGB was 5.7+/-4.3 years. The concordance between the results of the 2 biopsies was low (k=0.345). Diagnosis changed after the second MSGB in 23 cases, but in only 13 patients the second biopsy was considered clinically useful to revise the initial diagnosis.

Conclusion: There was a low concordance between two MSGB in patients with suspected pSS in our study. Despite this variability, performing a second MSGB changed the initial diagnosis in a minority of the patients.


Disclosure: T. Depinoy, None; V. Devauchelle-Pensec, Roche SAS, 5,Chugai Pharma France, 5; S. Jousse-Joulin, None; T. Marhadour, None; D. Guellec, None; P. Marcorelles, None; J. O. Pers, None; A. Saraux, Nordic Pharma, 5; D. Cornec, None.

To cite this abstract in AMA style:

Depinoy T, Devauchelle-Pensec V, Jousse-Joulin S, Marhadour T, Guellec D, Marcorelles P, Pers JO, Saraux A, Cornec D. Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-utility-of-a-second-minor-salivary-gland-biopsy-in-patients-with-suspected-sjogrens-syndrome-a-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-utility-of-a-second-minor-salivary-gland-biopsy-in-patients-with-suspected-sjogrens-syndrome-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology